All News

Regulatory & Standards

Fujifilm Invests $1.6 Billion into Expanding its Cell Culture Manufacturing Services
1 July 2022
Fujifilm Invests $1.6 Billion into Expanding its Cell Culture Manufacturing Services
Fujifilm Corporation has announced a
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
21 June 2022
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
Lisa Deschamps, AviadoBio CEO and
Market Access and Reimbursement Q&A with Nicola Redfern
21 June 2022
Market Access and Reimbursement Q&A with Nicola Redfern
Phacilitate's Advanced Therapies Europe speaker
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
21 June 2022
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
POPULAR NEWS ITEMS
Image
11 August 2022

GentiBio Collab with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for IBD

Image
10 August 2022

Stevenage Bioscience Hub’s Lab Hotel Joined by Inspira Pharmaceuticals

Image
9 August 2022

Pfizer Acquire Global Blood Therapeutics for $5.4 Billion

Two bluebird bio Gene Therapies Achieve Unanimous FDA Support
16 June 2022
Two bluebird bio Gene Therapies Achieve Unanimous FDA Support
Bluebird bio celebrates a big
Bruce Levine – CAR-T Past, Present and Future
6 June 2022
Bruce Levine – CAR-T Past, Present and Future
As we celebrate '10 Years
Market Access Report 2022
1 June 2022
Market Access Report 2022
The Phacilitate team explores market
10 Years of CAR-T: What Does the Future Hold for CAR-T?
20 May 2022
10 Years of CAR-T: What Does the Future Hold for CAR-T?
As our month of celebrating
Load more News
RECOMENDED TOPICS
Clinical Trials
Collaborations, Mergers & Acquisitions
Finance & Investment
Patient Access & Engagement
Regulatory & Standards
Reimbursement
Strategy
POPULAR NEWS ITEMS
Image

GentiBio Collab with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for IBD

Image

Stevenage Bioscience Hub’s Lab Hotel Joined by Inspira Pharmaceuticals

Image

Pfizer Acquire Global Blood Therapeutics for $5.4 Billion